Ignite Creation Date:
2024-05-06 @ 10:03 AM
Last Modification Date:
2024-10-26 @ 12:23 PM
Study NCT ID:
NCT03140176
Status:
TERMINATED
Last Update Posted:
2024-05-10
First Post:
2017-05-02
Brief Title:
Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
REAL-WORLD CLINICAL PATTERNS OF CARE AND OUTCOMES AMONG PATIENTS IN AFRICA MIDDLE EAST AFME WITH METASTATIC RENAL CELL CARCINOMA MRCC RECEIVING SUNITINIB AS FIRST LINE THERAPY OPTIMISE
Status:
TERMINATED
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The study was terminated early due to the inability to recruit the planned number of patients
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
OPTIMISE
Brief Summary:
OPTIMISE is designed to provide knowledge regarding the use of Sunitinib as 1st line treatment and 2nd line treatment selected Sunitinib-different sequence with respect to efficacy outcomes adverse events and health related QoL in the real life setting
Detailed Description:
OPTIMISE study objectives are dual and aim primarily to increase the knowledge regarding the outcomes from Sunitinib use on one hand and outcomes from the combined Sunitinib-2nd line sequence on the other hand in real life clinical practice
This will be addressed in many countries across AfME and in individual country cohorts to understand specificities and differences in use and outcomes
This will be addressed in many countries across AfME and in individual country cohorts to understand specificities and differences in use and outcomes
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None